Simplex Trading’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $120K | Sell |
14,300
-80,700
| -85% | -$736K | ﹤0.01% | 5323 |
|
|
2026
Q1 | $856K | Buy |
95,000
+16,600
| +21% | +$262K | ﹤0.01% | 2672 |
|
|
2025
Q4 | $1.43M | Sell |
78,400
-89,100
| -53% | -$1.5M | ﹤0.01% | 2262 |
|
|
2025
Q3 | $2.46M | Buy |
167,500
+107,200
| +178% | +$1.84M | ﹤0.01% | 2120 |
|
|
2025
Q2 | $1.1M | Buy |
60,300
+3,600
| +6% | +$73.4K | ﹤0.01% | 2691 |
|
|
2025
Q1 | $1.12M | Buy |
56,700
+26,900
| +90% | +$465K | ﹤0.01% | 2597 |
|
|
2024
Q4 | $511K | Buy |
29,800
+22,200
| +292% | +$418K | ﹤0.01% | 3508 |
|
|
2024
Q3 | $151K | Sell |
7,600
-900
| -11% | -$14K | ﹤0.01% | 4804 |
|
|
2024
Q2 | $95K | Buy |
8,500
+7,600
| +844% | +$63.8K | ﹤0.01% | 5424 |
|
|
2024
Q1 | $5K | Buy |
+900
| New | +$4.92K | ﹤0.01% | 7969 |
|
|
2023
Q4 | – | Sell |
-4,700
| Closed | -$16K | – | 8666 |
|
|
2023
Q3 | $16K | Sell |
4,700
-55,500
| -92% | -$214K | ﹤0.01% | 6794 |
|
|
2023
Q2 | $222K | Sell |
60,200
-6,800
| -10% | -$25.2K | ﹤0.01% | 4179 |
|
|
2023
Q1 | $221K | Sell |
67,000
-47,800
| -42% | -$165K | ﹤0.01% | 4202 |
|
|
2022
Q4 | $445K | Sell |
114,800
-3,700
| -3% | -$11.4K | ﹤0.01% | 3276 |
|
|
2022
Q3 | $287K | Buy |
118,500
+32,800
| +38% | +$78.7K | ﹤0.01% | 4134 |
|
|
2022
Q2 | $169K | Buy |
85,700
+68,000
| +384% | +$134K | ﹤0.01% | 4824 |
|
|
2022
Q1 | $32K | Sell |
17,700
-10,900
| -38% | -$17K | ﹤0.01% | 7686 |
|
|
2021
Q4 | $40K | Sell |
28,600
-227,000
| -89% | -$298K | ﹤0.01% | 7520 |
|
|
2021
Q3 | $406K | Hold |
255,600
| – | – | ﹤0.01% | 4417 |
|
|
2021
Q2 | $408K | Buy |
255,600
+253,136
| +10,273% | +$445K | ﹤0.01% | 4467 |
|
|
2021
Q1 | $433K | Buy |
2,464
+1,742
| +241% | +$3.99K | ﹤0.01% | 3575 |
|
|
2020
Q4 | $140K | Buy |
722
+576
| +395% | +$1.21K | ﹤0.01% | 5066 |
|
|
2020
Q3 | $34K | Sell |
146
-1,652
| -92% | -$4.53K | ﹤0.01% | 5953 |
|
|
2020
Q2 | $526K | Buy |
1,798
+38
| +2% | +$109 | ﹤0.01% | 2837 |
|
|
2020
Q1 | $506K | Buy |
+1,760
| New | +$6.08K | ﹤0.01% | 2568 |
|
|
2019
Q4 | – | Sell |
-70
| Closed | -$31K | – | 7196 |
|
|
2019
Q3 | $31K | Buy |
70
+1
| +1% | +$4 | ﹤0.01% | 5453 |
|
|
2019
Q2 | $26K | Buy |
+69
| New | +$305 | ﹤0.01% | 5382 |
|
|
2019
Q1 | – | Sell |
-9
| Closed | -$2K | – | 7043 |
|
|
2018
Q4 | $2K | Buy |
+9
| New | +$45 | ﹤0.01% | 6525 |
|
Other funds holding ADMA
RCMNY
CP
Simplex Trading's ADMA Position: Q2 2026 in Review
Simplex Trading reduced its ADMA Biologics (ADMA) stake by 49% in Q2 2026, selling an estimated $247K and leaving 27,876 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #4514.
Simplex Trading first reported a position in ADMA in Q3 2018 and has held it in 17 quarters since. The position peaked at $774K in Q3 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Simplex Trading held 27,876 shares of ADMA Biologics worth $233K as of Q2 2026.
- Simplex Trading sold 27,041 ADMA Biologics shares in Q2 2026, an estimated $247K.
- ADMA Biologics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #4514 holding.
- Simplex Trading first reported a position in ADMA Biologics in Q3 2018 and has held it in 17 quarters since.
- Simplex Trading's ADMA Biologics position peaked at $774K in Q3 2025.
- 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.